Loading... (0%)
About liver disease

Targeting
unmet patient
needs

Our R&D efforts are focused on
bringing new medicines to market
for patients with serious diseases
whose treatment options are
limited or non-existent,
as for NASH.

Read more

Our mission:
therapeutic
innovation

Our translational disease driven
approach is the strength of our R&D.
At Genfit, we believe in a full
comprehension of a disease
to discover therapeutic and
diagnostic new solutions.

Read more

Promising
drug
programs

The rationale of our pipeline
is to allow specialists physicians
to change life of their patients
thanks to our medicines.

Read more

Genfit is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions to address high unmet patient needs...
Learn more

News

12/18/2014: CM-CIC Securities
Buy, Target Price: €70

 

12/03/2014: Deutsche Bank US
Buy (opinion unchanged), Target Price: €110

Press releases
  • GENFIT: GFT505 treatment prevents evolution to cirrhosis
    12/16/2014
  • GENFIT raises Eur 21 million in a private placement
    12/10/2014
Events